J. Goldman & Co’s Amicus Therapeutics FOLD Stock Holding History

J. Goldman & Co’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-40,500	Closed	-$492K	–	383
2023 Q3	$492K	Buy	+40,500	New	+$522K	0.02%	279
2023 Q2	–	Sell	-60,000	Closed	-$665K	–	415
2023 Q1	$665K	Sell	60,000 -15,000	-20%	-$185K	0.03%	251
2022 Q4	$916K	Buy	+75,000	New	+$844K	0.05%	229
2022 Q1	–	Sell	-6,400	Closed	-$74K	–	391
2021 Q4	$74K	Sell	6,400 -162,000	-96%	-$1.81M	﹤0.01%	326
2021 Q3	$1.61M	Buy	+168,400	New	+$1.72M	0.08%	208
2019 Q4	–	Sell	-85,100	Closed	-$683K	–	292
2019 Q3	$683K	Buy	+85,100	New	+$924K	0.05%	206
2018 Q2	–	Sell	-130,000	Closed	-$1.96M	–	383
2018 Q1	$1.96M	Buy	+130,000	New	+$1.98M	0.08%	216

Other funds holding FOLD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

J. Goldman & Co's FOLD Position: Q2 2023 in Review

J. Goldman & Co sold out of Amicus Therapeutics (FOLD) in Q2 2023, closing a stake of 387,654 shares — an estimated $4.3M sold.

J. Goldman & Co first reported a position in FOLD in Q4 2014 and held it in 10 quarters. The position peaked at $4.3M in Q1 2023. 216 funds tracked by Wall St. Rank hold FOLD as of Q2 2023.

J. Goldman & Co reported no remaining Amicus Therapeutics position as of Q2 2023 after selling out during the quarter.
J. Goldman & Co sold 387,654 Amicus Therapeutics shares in Q2 2023, an estimated $4.3M.
J. Goldman & Co first reported a position in Amicus Therapeutics in Q4 2014 and held it in 10 quarters.
J. Goldman & Co's Amicus Therapeutics position peaked at $4.3M in Q1 2023.
216 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2023.

Based on J. Goldman & Co's 13F filing for Q2 2023, filed 14 Aug 2023.